IEZZI, LAURA
 Distribuzione geografica
Continente #
EU - Europa 563
NA - Nord America 227
AS - Asia 88
SA - Sud America 10
AF - Africa 4
OC - Oceania 2
Totale 894
Nazione #
FR - Francia 352
US - Stati Uniti d'America 223
IT - Italia 64
NL - Olanda 48
IN - India 31
SE - Svezia 28
VN - Vietnam 28
IE - Irlanda 24
GB - Regno Unito 12
BR - Brasile 9
CN - Cina 9
CZ - Repubblica Ceca 9
DE - Germania 7
UA - Ucraina 5
ES - Italia 4
TH - Thailandia 4
BE - Belgio 3
BH - Bahrain 3
CA - Canada 3
HR - Croazia 3
KR - Corea 3
TW - Taiwan 3
AU - Australia 2
EG - Egitto 2
JP - Giappone 2
PK - Pakistan 2
RU - Federazione Russa 2
CI - Costa d'Avorio 1
FI - Finlandia 1
IQ - Iraq 1
IR - Iran 1
MX - Messico 1
NG - Nigeria 1
PE - Perù 1
PL - Polonia 1
TR - Turchia 1
Totale 894
Città #
Ashburn 93
Paris 52
Groningen 41
Chieti 31
Dong Ket 28
Stockholm 28
Dublin 24
Boardman 16
Encino 10
São José dos Campos 9
Delhi 7
Pescara 7
Bengaluru 5
Chesterfield 5
Houston 5
London 5
Padova 4
Liège 3
Manama 3
Mumbai 3
Pune 3
Ahmedabad 2
Gurgaon 2
Hyderabad 2
Islamabad 2
Madrid 2
Munich 2
New York 2
Palo Alto 2
San Jose 2
Seattle 2
Sydney 2
Tucson 2
Washington 2
Zagreb 2
Abidjan 1
Ado-Ekiti 1
Amsterdam 1
Baghdad 1
Basking Ridge 1
Bologna 1
Boston 1
Bursa 1
Caldogno 1
Cento 1
Chennai 1
Chicago 1
Clemmons 1
Cleveland 1
Colchester 1
Columbus 1
Costa Mesa 1
Council Bluffs 1
El Puerto De Santa María 1
Fuzhou 1
Goyang-si 1
Hamm 1
Helsinki 1
Huntington 1
Irvine 1
Krakow 1
Kwangju 1
L'aquila 1
Lancaster 1
Laurentides 1
Leawood 1
Lima 1
Lindon 1
Mexico City 1
Miaoli 1
Milan 1
Monmouth Junction 1
Mountain View 1
Naples 1
New Taipei 1
O Fallon 1
Pavia 1
Redmond 1
Rome 1
Roseto Degli Abruzzi 1
Sangli 1
Santander 1
Savigliano 1
Seoul 1
Shimla 1
Spanaway 1
Tokyo 1
Toronto 1
Trumbull 1
Utrecht 1
Veenendaal 1
Vizianagaram 1
Wakayama 1
Waterdown 1
Totale 469
Nome #
A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression, file 114fed17-b83b-46da-91ef-667cebee5d84 308
Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting, file e4233f17-5bd2-2860-e053-6605fe0a460a 115
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience, file e4233f16-1a32-2860-e053-6605fe0a460a 100
Long-term outcome of breast cancer patients with pathologic N3a lymph node stage, file e4233f16-15f4-2860-e053-6605fe0a460a 85
null, file e4233f17-03df-2860-e053-6605fe0a460a 84
Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin, file e4233f15-d34c-2860-e053-6605fe0a460a 23
Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial., file e4233f16-15f7-2860-e053-6605fe0a460a 23
"Triple positive" early breast cancer: An observational multicenter retrospective analysis of outcome, file e4233f16-2338-2860-e053-6605fe0a460a 22
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials, file e4233f17-03db-2860-e053-6605fe0a460a 19
Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage? Reply to Kadri Altundag, file e4233f16-1dd0-2860-e053-6605fe0a460a 18
Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer, file e4233f16-27e8-2860-e053-6605fe0a460a 18
Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting, file e4233f17-8622-2860-e053-6605fe0a460a 15
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study, file e4233f19-3bdd-2860-e053-6605fe0a460a 12
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study, file 3a4b6c7c-5bce-4ec1-8fd7-7ffb4638d71b 11
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting, file eefa9c0c-0a62-48a3-b14b-64ceadad9992 10
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study, file e4233f16-3e89-2860-e053-6605fe0a460a 9
Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting, file c5838e51-8b69-42be-b4e0-7c0567e424dd 8
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting, file 26826aa7-b457-45c4-ad25-a9a93cb38bfd 7
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study, file e4233f15-1297-2860-e053-6605fe0a460a 6
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience, file e4233f17-03d7-2860-e053-6605fe0a460a 3
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer, file e4233f15-6e57-2860-e053-6605fe0a460a 2
Totale 898
Categoria #
all - tutte 1.980
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.980


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202012 0 0 1 0 0 0 0 0 8 0 3 0
2020/202188 0 7 3 1 4 12 6 9 7 6 3 30
2021/202231 4 2 9 3 1 1 3 2 2 2 1 1
2022/2023115 1 1 2 1 4 15 12 14 4 0 52 9
2023/2024645 16 24 18 17 11 300 153 9 85 12 0 0
Totale 898